Skip to main content
. 2022 Feb 28;14(5):1252. doi: 10.3390/cancers14051252

Figure 3.

Figure 3

Overall cisplatin sensitivity scores of the primary breast cancer samples. (A) Criteria for ex vivo cisplatin sensitivity scoring. (B) The HE, EdU, TUNEL and average ex vivo sensitivity scores using the criteria defined in (A). M-numbers represent individual primary mammary tumors.